Natera (NTRA) shares surged 13.05% in post-market trading Thursday, after the genetic testing company reported second-quarter financial results that significantly exceeded analyst expectations and raised its full-year revenue forecast.

The company posted Q2 revenue of $752.8 million, a 37.7% increase year-over-year, well above the consensus estimate of $660.7 million. Adjusted loss per share narrowed to $0.47, beating the expected loss of $0.49. Natera also lifted its 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, up from the prior $2.74 billion to $2.82 billion and above the FactSet consensus of $2.80 billion. The strong performance was driven by higher overall test volumes, with oncology test volumes surging 57% year-over-year.

Management attributed the improved results to robust demand for its Signatera molecular residual disease test and continued progress in reducing cost of revenues. The company also provided an outlook for positive cash flow in 2026, reinforcing investor confidence in its growth trajectory.